SLDB Solid Biosciences Inc

Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking . A replay will be available on the Company’s website following the event.

Institutional investors interested in meeting with management during the conference may reach out to their Chardan representative.

About Solid Biosciences

Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .

Solid Biosciences Investor Contact:

David Carey

FINN Partners

212-867-1768

Solid Biosciences Media Contact:

Tim Palmer

Associate Director, Corporate Communications

607-760-4223



EN
21/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted stock units (“RSUs”) to four newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s...

 PRESS RELEASE

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at Upcoming Scientific Meetings CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from its neuromuscular and cardiac programs at the World Muscle Society (WMS) 2025 Annual International Congress, October 7-11, 2025, in Vienna, Austria, and at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress, October 7-12, 2025, in Seville, Spain. “Our presentations at WMS and ESGCT will high...

 PRESS RELEASE

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual ...

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation investigational gene therapy intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG), September 26-28, 2025, in Stresa, Ita...

 PRESS RELEASE

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the...

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass...

 PRESS RELEASE

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Citi Biopharma Back to School ConferenceBo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 2, 2025, at 1:45 p.m. ET. A live webcast will be available by . Cantor Global Healthcare ConferenceMr. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch